[Skip to Content]
[Skip to Content Landing]
Views 1,235
Citations 0
Comment & Response
March 10, 2015

Left Atrial Appendage Closure for Atrial Fibrillation

Author Affiliations
  • 1Krankenanstalt Rudolfstiftung, Wien, Austria
  • 2Sana Kliniken, Lübeck, Germany
JAMA. 2015;313(10):1057. doi:10.1001/jama.2015.0682

To the Editor The study by Dr Reddy and colleagues1 reported the 3.8-year follow-up of the PROTECT AF trial that randomized patients with atrial fibrillation (AF) to receive percutaneous left atrial appendage (LAA) closure with the WATCHMAN device or warfarin. We had a number of questions and concerns about the study.

First, patients randomized to receive warfarin were older and more often had cardiovascular comorbidities and permanent AF than the patients randomized to receive the LAA closure. In Table 1 in the article, P values were missing, so it is unclear if these differences were statistically significant and may in part explain the higher mortality in the warfarin group.